文献速递炎症性肠病

既往TNF拮抗剂暴露对溃疡性结肠炎高级疗法诱导缓解疗效的差异影响

Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-26

本系统综述与Meta分析纳入17项随机对照试验共8871例中重度溃疡性结肠炎成人患者,比较不同高级疗法对比安慰剂诱导临床缓解的疗效是否受既往TNF拮抗剂暴露影响。结果显示淋巴细胞转运抑制剂在未暴露患者中更有效(5项试验;OR 1.88;95%CI 1.02-3.49),JAK抑制剂在未暴露患者中疗效较低(6项试验;OR比值比 0.47;95%CI 0.22-1.01),选择性IL-23拮抗剂无显著差异(6项试验;OR比值比 1.07;95%CI 0.64-1.80)。

要点

  • 淋巴细胞转运抑制剂在TNF拮抗剂未暴露患者中诱导缓解疗效更优(5项试验;OR 1.88;95%CI 1.02-3.49)。
  • JAK抑制剂在TNF拮抗剂未暴露患者中疗效较低(6项试验;OR比值比 0.47;95%CI 0.22-1.01)。
  • 选择性IL-23拮抗剂在未暴露与暴露患者间无显著差异(6项试验;OR比值比 1.07;95%CI 0.64-1.80)。

核心结论

  • 不同高级疗法诱导溃疡性结肠炎缓解的疗效因既往TNF拮抗剂暴露而存在显著异质性,JAK抑制剂可能增效而淋巴细胞转运抑制剂可能减效。
  • 作者认为有必要进一步研究上述观察的机制基础。

研究设计与样本

  • 系统综述与Meta分析,检索多个数据库至2024年6月30日,纳入17项随机对照试验共8871例中重度溃疡性结肠炎成人患者,比较不同高级疗法与安慰剂诱导临床缓解的疗效,并按既往TNF拮抗剂暴露分层。
  • 计算活动药对比安慰剂达到缓解的OR比值比,比较TNF拮抗剂未暴露与暴露患者间的差异;按主要作用机制分组:淋巴细胞转运抑制剂(抗整合素和S1P受体调节剂)、抗白细胞介素(IL-12/23拮抗剂和选择性IL-23拮抗剂)及JAK抑制剂。

主要发现

  • 淋巴细胞转运抑制剂在TNF拮抗剂未暴露患者中较暴露患者更有效(5项试验;OR 1.88;95%CI 1.02-3.49)。
  • JAK抑制剂在TNF拮抗剂未暴露患者中较暴露患者疗效更低(6项试验;OR比值比 0.47;95%CI 0.22-1.01)。
  • 选择性IL-23拮抗剂在TNF拮抗剂未暴露与暴露患者间对比安慰剂的疗效无显著差异(6项试验;OR比值比 1.07;95%CI 0.64-1.80)。
  • 各分析间异质性极小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We sought to ascertain how prior exposure to tumor necrosis factor (TNF) antagonists impacts treatment response with various classes of advanced therapies in patients with ulcerative colitis (UC), through a systematic review and meta-analysis. METHODS: Through a systematic review of multiple databases through June 30, 2024, we identified 17 randomized controlled trials in 8871 adults with moderate-severe UC who were treated with different advanced therapies vs placebo, and reported efficacy in induction of clinical remission, stratified by prior exposure to TNF antagonists. We calculated the ratio of odds ratio of achieving remission with active drug vs placebo, in TNF antagonist-naïve vs TNF antagonist-exposed patients. We grouped advanced therapies based on primary mechanism of action: lymphocyte trafficking inhibitors (anti-integrins and sphingosine-1 phosphate [S1P] receptor modulators), anti-interleukins (interleukin-12/23 antagonist and selective interleukin-23 antagonists) and Janus kinase inhibitors. RESULTS: Lymphocyte trafficking inhibitors were more efficacious in TNF antagonist-naïve vs exposed patients (5 trials; odds ratio [OR], 1.88; 95% confidence interval [CI], 1.02-3.49), whereas JAK inhibitors were less efficacious in TNF antagonist-naïve vs exposed patients (6 trials; ratio of OR, 0.47; 95% CI, 0.22-1.01). No significant difference was observed in efficacy of selective interleukin-23 antagonists vs placebo in TNF antagonist-naïve vs exposed patients (6 trials; ratio of OR, 1.07; 95% CI, 0.64-1.80). There was minimal heterogeneity across analyses. CONCLUSIONS: There is significant heterogeneity of treatment efficacy with different advanced therapies in inducing remission in patients with UC based on prior exposure to TNF antagonists, with plausible potentiation of JAK inhibitors and attenuation of lymphocyte trafficking inhibitors. Future studies on the mechanistic basis for these observations are warranted.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee HH, Solitano V, Singh S, et al. Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists. Clin Gastroenterol Hepatol. 2024. PMID: 39732355. doi:10.1016/j.cgh.2024.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。